Gleiter C H, Nilsson E, Mühlbauer B, Antonin K H, Bieck P R
Human Pharmacology Institute, Ciba-Geigy GmbH, Tübingen, Federal Republic of Germany.
J Neural Transm Gen Sect. 1992;89(1-2):129-33. doi: 10.1007/BF01245359.
MAO-B activity was compared in healthy volunteers following oral treatment with clinically effective doses of the selective MAO-A inhibitors brofaromine (100 mg q.d. for 14 days), moclobemide (150 mg t.i.d. for 14 days) and clorgyline (5 mg t.i.d. for 10 days). Brofaromine and clorgyline did not alter platelet MAO activity. Following moclobemide treatment, MAO-B activity was reduced by 32% (p less than 0.05). It recovered during the 5 subsequent days after discontinuation of treatment. These results confirm earlier findings. The explanation for this finding may be that metabolites of moclobemide are active inhibitors of MAO-B.
在健康志愿者口服临床有效剂量的选择性单胺氧化酶-A抑制剂溴法罗明（每日100毫克，共14天）、吗氯贝胺（每日3次，每次150毫克，共14天）和氯吉兰（每日3次，每次5毫克，共10天）后，对单胺氧化酶-B（MAO-B）活性进行了比较。溴法罗明和氯吉兰未改变血小板MAO活性。在吗氯贝胺治疗后，MAO-B活性降低了32%（p<0.05）。在停药后的随后5天内其活性恢复。这些结果证实了早期的发现。这一发现的解释可能是吗氯贝胺的代谢产物是MAO-B的活性抑制剂。
